LV12910B - Pharmaceutical composition comprising a combination of metformin and glibenclamide - Google Patents

Pharmaceutical composition comprising a combination of metformin and glibenclamide Download PDF

Info

Publication number
LV12910B
LV12910B LVP-02-94A LV020094A LV12910B LV 12910 B LV12910 B LV 12910B LV 020094 A LV020094 A LV 020094A LV 12910 B LV12910 B LV 12910B
Authority
LV
Latvia
Prior art keywords
metformin
glyburide
pharmaceutical composition
dose
combination
Prior art date
Application number
LVP-02-94A
Other languages
English (en)
Latvian (lv)
Inventor
Beth Anne Piper
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/432,465 external-priority patent/US6586438B2/en
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of LV12910B publication Critical patent/LV12910B/lv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LVP-02-94A 1999-11-03 2002-06-03 Pharmaceutical composition comprising a combination of metformin and glibenclamide LV12910B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/432,465 US6586438B2 (en) 1999-11-03 1999-11-03 Antidiabetic formulation and method
US09/460,920 US7598262B2 (en) 1999-11-03 1999-12-14 Method for treating diabetes

Publications (1)

Publication Number Publication Date
LV12910B true LV12910B (en) 2003-05-20

Family

ID=27029501

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-02-94A LV12910B (en) 1999-11-03 2002-06-03 Pharmaceutical composition comprising a combination of metformin and glibenclamide

Country Status (23)

Country Link
EP (1) EP1229918B1 (https=)
JP (1) JP5183844B2 (https=)
KR (1) KR20070089259A (https=)
CN (1) CN1450902A (https=)
AR (1) AR026356A1 (https=)
AT (1) ATE390140T1 (https=)
AU (1) AU780106B2 (https=)
BR (1) BR0015294A (https=)
CA (1) CA2389928C (https=)
EE (1) EE05260B1 (https=)
HU (1) HU229352B1 (https=)
IL (1) IL149139A0 (https=)
LT (1) LT5058B (https=)
LV (1) LV12910B (https=)
MX (1) MXPA02004282A (https=)
NO (1) NO330026B1 (https=)
NZ (1) NZ518278A (https=)
PL (1) PL199278B1 (https=)
RU (1) RU2275915C2 (https=)
SK (1) SK287810B6 (https=)
TW (1) TWI280125B (https=)
UY (1) UY26424A1 (https=)
WO (1) WO2001032157A2 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7563774B2 (en) 2000-06-29 2009-07-21 Metabasis Therapeutics, Inc. Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
FR2816840B1 (fr) 2000-11-17 2004-04-09 Flamel Tech Sa Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
FR2825023B1 (fr) * 2001-05-23 2005-04-15 Flamel Tech Sa Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
WO2003011273A1 (en) * 2001-07-31 2003-02-13 The Governement Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Metformin in the treatment of hyperglycemic conditions
CA2480826C (fr) 2002-04-09 2012-02-07 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
WO2003105809A1 (en) 2002-06-17 2003-12-24 Themis Laboratories Private Limited Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
US20080090859A1 (en) * 2003-10-30 2008-04-17 Tioga Pharmaceuticals, Inc. Use of Selective Opiate Receptor Modulators In the Treatment Of Neuropathy
US7442720B2 (en) * 2003-12-19 2008-10-28 Omega Bio-Pharma (I.P.3) Limited Compositions and methods for treating diabetes
KR20070005738A (ko) * 2004-05-03 2007-01-10 오메가 바이오 파마(아이.피.3) 리미티드 콜레스테롤 과잉혈증 및 당뇨병의 합병증을 치료하기 위한시스테아민
CN101801351B (zh) 2007-07-19 2012-12-12 武田药品工业株式会社 包含阿格列汀和盐酸二甲双胍的固体制剂
MX2010002695A (es) 2007-09-10 2010-04-01 Janssen Pharmaceutica Nv Proceso para la preparacion de compuestos utiles como inhibidores de transportador de glucosa dependiente de sodio (sglt).
RU2372911C1 (ru) * 2008-03-12 2009-11-20 Николай Евгеньевич Староверов Полиморфная аналоговая терапия
CN102256618A (zh) 2008-10-17 2011-11-23 赛诺菲-安万特德国有限公司 胰岛素和glp-1激动剂的组合
US9056850B2 (en) 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
NZ599847A (en) 2009-11-13 2013-09-27 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
TR201809460T4 (tr) 2009-11-13 2018-07-23 Sanofi Aventis Deutschland Bir GLP- 1-agonisti, bir insülin ve metiyonin içeren farmasötik bileşim.
TWI599360B (zh) 2010-05-11 2017-09-21 健生藥品公司 醫藥調配物
WO2012028172A1 (en) 2010-08-30 2012-03-08 Sanofi-Aventis Deutschland Gmbh Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
CN103458919A (zh) * 2011-02-02 2013-12-18 赛诺菲-安万特德国有限公司 在2型糖尿病患者中预防低血糖症
US20120277147A1 (en) * 2011-03-29 2012-11-01 Sanofi-Aventis Deutschland Gmbh Prevention of hypoglycaemia in diabetes mellitus type 2 patients
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
PE20171622A1 (es) 2014-12-12 2017-11-02 Sanofi Aventis Deutschland Formulacion de relacion fija de insulina glargina/lixisenatida
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
CN110804017A (zh) * 2019-10-31 2020-02-18 天津大学 磺酰脲化合物与二甲双胍成盐、制备方法和应用
CN113143940A (zh) * 2020-12-30 2021-07-23 成都恒瑞制药有限公司 一种抗糖尿病药物组合物的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
DE3833439A1 (de) * 1988-10-01 1991-09-12 Hoechst Ag Verfahren zur mikronisierung von glibenclamid
DK36392D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
IT1276130B1 (it) * 1995-11-14 1997-10-27 Gentili Ist Spa Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
ATE355840T1 (de) 1997-06-18 2007-03-15 Smithkline Beecham Plc Behandlung der diabetes mit thiazolidindione und metformin
ATE261935T1 (de) * 1997-12-08 2004-04-15 Bristol Myers Squibb Co Neue metformin salze und verfahren
ATE250418T1 (de) * 1998-07-15 2003-10-15 Merck Sante Sas Tabletten enthaltend eine kombination von glibenclamid und metformin
EP2620443A1 (en) 2012-01-25 2013-07-31 Galecto Biotech AB Novel galactoside inhibitors of galectins

Also Published As

Publication number Publication date
CA2389928C (en) 2010-03-23
WO2001032157A2 (en) 2001-05-10
HUP0300218A3 (en) 2006-02-28
KR20070089259A (ko) 2007-08-30
EP1229918A2 (en) 2002-08-14
UY26424A1 (es) 2001-05-31
EP1229918B1 (en) 2008-03-26
NO20022087L (no) 2002-06-24
LT5058B (lt) 2003-09-25
NO20022087D0 (no) 2002-05-02
LT2002063A (en) 2003-06-25
TWI280125B (en) 2007-05-01
HUP0300218A2 (hu) 2003-06-28
NO330026B1 (no) 2011-02-07
EE200200242A (et) 2003-12-15
NZ518278A (en) 2004-10-29
PL364885A1 (en) 2004-12-27
EE05260B1 (et) 2010-02-15
JP2003519621A (ja) 2003-06-24
IL149139A0 (en) 2002-11-10
JP5183844B2 (ja) 2013-04-17
RU2002114820A (ru) 2004-03-10
MXPA02004282A (es) 2003-02-17
CN1450902A (zh) 2003-10-22
SK287810B6 (sk) 2011-10-04
RU2275915C2 (ru) 2006-05-10
AU780106B2 (en) 2005-03-03
SK5002002A3 (en) 2004-05-04
BR0015294A (pt) 2003-07-15
ATE390140T1 (de) 2008-04-15
HU229352B1 (en) 2013-11-28
AR026356A1 (es) 2003-02-05
WO2001032157A3 (en) 2002-01-24
CA2389928A1 (en) 2001-05-10
PL199278B1 (pl) 2008-09-30
AU1082601A (en) 2001-05-14

Similar Documents

Publication Publication Date Title
US7598262B2 (en) Method for treating diabetes
EP1229918B1 (en) Pharmaceutical composition comprising a combination of metformin and glibenclamide
JP2003519621A5 (https=)
EP1455793A2 (en) Antidiabetic formulation and method
AU8022900B2 (https=)
AU2002357095B2 (en) Antidiabetic formulation and method